Veru Inc. filings document regulatory disclosures for a Wisconsin biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under VERU. Recent 8-K reports cover financial results, clinical program updates, material agreements, settlement of promissory-note obligations, security-holder rights, and capital-structure actions, including the completed 1-for-10 reverse stock split.
Proxy and annual-meeting records describe board elections, auditor ratification, executive compensation votes, and amendments to the 2018 Equity Incentive Plan. The filing record also includes Nasdaq listing-compliance disclosures and exhibits tied to Veru’s enobosarm and sabizabulin development programs.
Veru Inc. reported a smaller net loss while remaining a pre‑revenue, late‑stage biotech focused on enobosarm and sabizabulin. For the six months ended March 31, 2026, net loss was $8.1 million versus $16.8 million a year earlier, helped by a $3.8 million gain on equity securities and lower operating expenses.
The company had $27.6 million in cash, cash equivalents, and restricted cash and used $15.1 million in operating cash over six months. Management states there is substantial doubt about Veru’s ability to continue as a going concern over the next 12 months without additional capital.
Veru sold its FC2 condom business and ENTADFI rights, reshaping itself around obesity and cardiovascular drug candidates. It raised about $23.4 million in an October 2025 equity offering that included common stock, pre‑funded warrants, and 16.8 million tradable warrants, but now depends on future financings to fund development.
Veru Inc. reported fiscal 2026 second quarter results and highlighted progress in its Phase 2b PLATEAU obesity trial of enobosarm plus semaglutide, which is actively enrolling and targeting an interim analysis in the first quarter of calendar 2027.
For the quarter ended March 31, 2026, Veru reduced its net loss to $2.7 million from $7.9 million a year earlier, helped by higher non-operating income of $4.1 million. Operating expenses fell to $7.2 million from $9.1 million as both research and development and general and administrative costs declined.
For the first six months of fiscal 2026, net loss narrowed to $8.1 million from $16.8 million. Cash, cash equivalents and restricted cash increased to $27.6 million as of March 31, 2026, supported by $23.4 million of net cash provided by financing activities during the period.
VERU INC. President and CEO Mitchell Steiner received a grant of options on 604,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, reflecting a multi‑year compensation award tied to continued service.
VERU INC. Chief Admin Officer and CFO Michele Greco received a grant of options to purchase 164,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related awards, not open-market share purchases or sales.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. After this grant, Greco holds 164,000 options directly.
VERU INC. director Loren Mark Katzovitz received a grant of stock options covering 102,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Hyun Grace received a grant of options to buy 97,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related options, not an open-market purchase, and give her the right to buy shares in the future.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, with all unexercised options expiring on May 4, 2036. After this grant, she holds options for 97,000 shares directly.
VERU INC. director Michael L. Rankowitz received a grant of options on 100,000 shares of Veru common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Lucy Lu reported receiving a grant of 104,000 common stock options as compensation. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and Lu holds 104,000 options following this grant.
VERU INC. disclosed that Chief Scientific Officer K. Gary Barnette received a compensation-related grant of stock options. The award covers 160,000 options to acquire Veru common shares at an exercise price of $2.25 per share, with all options held directly after the grant.
According to the vesting terms, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. This filing reflects an equity incentive grant rather than an open-market purchase or sale.
VERU INC. Chief Corporate Officer Harry Fisch received a grant of stock options covering 160,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036.
According to the vesting schedule, one-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029. Following this grant, Fisch holds 160,000 options to acquire VERU common shares directly, reflecting a compensation-related equity award rather than an open-market purchase.